[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"human-papillomavirus-hpv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:human-papillomavirus-hpv":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,82,107,132,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100651303","phase-2-combination-bevacizumab-and-prgn-2012-in-adults-with-recurrent-respiratory-papillomatosis-rrp-100651303",false,"NCT07756840","Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)","A Phase II Study of Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)","* INCLUSION CRITERIA:\n* Histological or cytological diagnosis of RRP confirmed by pathology report. Note: If there is no documentation or archival sample, a biopsy will be done to confirm the diagnosis.\n* Age \\>= 18 years old.\n* A history of 2 or more surgeries or use of IV bevacizumab in order to control laryngeal and\u002For tracheal RRP within 12 months prior to the study treatment initiation.\n* Previous treatment with PRGN-2012 (zopapogene imadenovec \\[Papzimeos\\]).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Participants must have an adequate organ and marrow function as defined below:\n\n  * White blood cells (WBC) \\>2,000\u002FmcL\n  * Absolute neutrophil count (ANC) \\>= 1,000\u002FmcL\n  * Hemoglobin \\> 9.0 g\u002FdL\n  * Platelets \\>= 100,000\u002FmcL\n  * Total bilirubin \\\u003C= 1.5 mg\u002FdL. Note: participants with Gilbert s Syndrome must have a total bilirubin \\\u003C 3.0 mg\u002FdL\n  * Aspartate aminotransferase (AST) \\\u003C= 2.5 X institutional upper limit of normal (ULN)\n  * Alanine aminotransferase (ALT) \\\u003C=2.5 X institutional ULN\n  * Creatinine within normal institutional limits OR Creatinine Clearance (CrCl) \\>= 60 mL\u002Fmin\u002F1.73 m\\^2 for participants with creatinine levels above institutional normal (calculated using the Cockcroft-Gault formula).\n  * Prothrombin time (PT) \u002F International normalized ratio (INR) and Partial thromboplastin time (PTT) \\\u003C= 1 X institutional ULN. In participants on anticoagulation, coagulation tests should be within a therapeutic range.\n  * Urinalysis Urine dipstick \\\u003C 2+ proteinuria. Participants with \\>= 2+ proteinuria on dipstick urinalysis should undergo a 24- hour urine collection and must demonstrate \\\u003C= 1g of protein in 24 hours to be eligible\n* Women of child-bearing potential (WOCBP) must agree to use a highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization, abstinence) for the duration of treatment and up to 6 months after completion of the study treatment.\n\nMen must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of treatment and up to 4 months after the last dose of study drugs. We also recommend men with partners of childbearing potential ask their partners to be on highly effective birth control (hormonal, IUD, surgical sterilization). Men must not freeze or donate sperm within the same period.\n\n* Women who are breastfeeding or plan to breastfeed must agree to discontinue breastfeeding from study treatment initiation.\n* Ability of participant to understand and sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* History of significant cardiovascular disease or thromboembolic event: cerebral vascular accident\u002Fstroke, myocardial infarction, unstable angina, congestive heart failure (\\>= New York Heart Association Classification Class II) occurring within 12 months prior to the study treatment initiation\n* Serious cardiac arrhythmia requiring medication as assessed by electrocardiogram (EKG) at screening.\n* Any investigational agents within 4 weeks prior to the study treatment initiation.\n* Systemic medical RRP therapy within 4 weeks or 3 half-lives, whichever is longer prior to the study treatment initiation.\n* Participants with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to the study treatment initiation. Note: Inhaled, topical intranasal or intraocular steroids, and adrenal replacement doses \\\u003C10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n* History of abdominal fistula or gastrointestinal perforation within 12 months prior to the study treatment initiation.\n* Major surgery within 4 weeks prior to the study treatment initiation. Note: The surgery is considered major if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges).\n* Non-healing wounds, active ulcer, or untreated bone fracture.\n* History of hemoptysis (\\>2.5 mL of bright red blood per episode) within 1 month prior to the study treatment initiation.\n* History of serious hemorrhage (CTCAE Grade 4) within 12 months prior to the study treatment initiation.\n* Evidence of bleeding diathesis or significant coagulopathy (with or without current therapeutic anticoagulation).\n* Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to the study treatment initiation.\n* Inadequately controlled hypertension (defined as systolic blood pressure (BP) \\>150 mmHg and\u002For diastolic blood pressure \\> 100 mmHg). Note: an average of 3 BP readings on 2 sessions will be used to measure blood pressure if the initial reading indicates inadequately controlled hypertension. Anti-hypertensive therapy to achieve blood pressures below these parameters is allowed.\n* Prior history of hypertensive crisis or hypertensive encephalopathy.\n* Persisting toxicity related to prior therapy of Grade \\>1 per CTCAE. Note: Alopecia, sensory neuropathy Grade \\\u003C= 2 are acceptable.\n* Known, active alcohol or drug abuse.\n* History of allergy to study drug components.\n* History of \\>= Grade 3 per CTCAE infusion-related reaction to bevacizumab or PRGN-2012.\n* Pregnancy confirmed with beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test in WOCBP at screening.\n* Uncontrolled symptomatic, intercurrent illness evaluated by medical history, physical exam, and labs, or social situations that would unacceptably increase risk for the participant or impair the ability to evaluate the endpoints of the study, or that would limit compliance with study requirements.","ALL","18 Years","120 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Background:\n\nRecurrent respiratory papillomatosis (RRP) is a rare disease that causes wart-like growths called papillomas to grow in the airway, most often in the voice box, windpipe, or lungs. These growths can make it hard to speak or breathe. Surgery can remove the papillomas, but they often come back. In some cases, they can become cancerous.\n\nObjective:\n\nThis study istesting whether two treatments used together (PRGN-2012, a vaccine-based treatment and bevacizumab, a drug that affects blood vessel growth) can help control RRP and reduce the chance that papillomas will grow back.\n\nEligibility:\n\nAdults aged 18 years and older may be able to join the study if they have RRP and meet certain treatment history requirements. This may include people who have previously received PRGN-2012 or bevacizumab, or people who have needed more than 2 surgeries to remove papillomas.\n\nDesign:\n\nBefore starting treatment, participants will have screening tests to make sure the study is safe for them. These tests may include a physical exam with blood and urine tests, heart function testing, imaging scans, and an endoscopy. During an endoscopy, a thin, flexible tube with a small camera will look at the inside of the nose, throat, voice box, and upper windpipe.\n\nParticipants will receive study treatment during 7 clinic visits over about 6 months. Bevacizumab is given through a vein amd PRGEN-2012 is given as an injection under the skin of the arm or leg. Participants may receive 1 or both drugs at each visit.\n\nAfter completing treatmen, participants will return for 4 follow-up visits over 1 year. These visits may include repeat imaging, blood and urine tests, and other exams. After that, the study team will contact participantsby phone or email every 3 months for 2 years.\n\nIf their RRP gets worse during the follow-up period, they may be able to receive a second course of treatment using the same schedule....",[27,28,29,30,31,32],"Respiratory Recurrent Papillomatosis (RRP)","Human Papillomavirus (HPV)","Papillomavirus Infection","Laryngeal Diseases","Tracheal Diseases","Respiratory Tract Neoplasm",[34,35,36,37],"HPV Vaccine","Gardasil","Papzimeos (zopapogene imadenovec-drba)","Bevacizumab (Avastin)","NOT_YET_RECRUITING","2026-08-20",{"date":41,"type":42},"2026-08-21","ACTUAL",{"date":44,"type":21},"2026-08-26",{"date":46,"type":21},"2030-07-01",{"name":48,"class":49},"National Cancer Institute (NCI)","NIH",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100632938","c-3002-enhancing-cervical-cancer-screening-access-and-follow-up-care-at-cascade-clinical-sites-in-the-united-states-100632938","NCT07520188","C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States","CASCADE3002","Aim 1b Inclusion Criteria\n\n* women with Human Immunodeficiency Virus (HIV) receive care\n* ages between 25- 49\n* eligible for cervical cancer screening per national US guidelines\n\nAim 1b Exclusion Criteria • Women without an intact cervix.\n\nAim 2 Inclusion Criteria:\n\n* Clinical team members who work and provide care to women living with HIV at three clinical locations: the Center for Infectious Diseases (CID) at the University of Maryland School of Medicine in Baltimore, MD; Ponce de Leon Clinic at Emory University in Atlanta, GA; and Albany Area Primary Health Care in Albany, GA. a\n* Clinical team members will include: providers (Physicians, Nurse practitioners, Physician's Assistants, Nurses, Nursing Assistants, Medical Assistants, Pharmacists), laboratory members, or other staff involved in clinic operations.\n\nAim 2 Exclusion Criteria\n\n• Individuals who do not work for the Center for Infectious Diseases (CID) at the University of Maryland School of Medicine in Baltimore, MD or the Ponce de Leon Clinic at Emory University in Atlanta, GA",true,"25 Years","49 Years",{"count":62,"type":21},3500,"OBSERVATIONAL","The purpose of the CASCADE-3002 project is to improve access to cervical cancer screening among women with Human Immunodeficiency Virus (HIV) receiving care at U.S.-based CASCADE clinical sites. This study will assess the cervical cancer screening cascade and identify multilevel factors that impede access to screening among women with HIV attending Infectious Disease clinics in Georgia and Maryland. In parallel, the study will explore and develop implementation strategies for human papillomavirus (HPV) self-collection to increase screening uptake, adherence, and appropriate clinical follow-up in this population at elevated risk for cervical cancer.\n\nCervical cancer remains a preventable malignancy; however, women with HIV are at substantially increased risk and experience higher rates of cervical cancer compared with women without HIV. The World Health Organization has called for the global elimination of cervical cancer as a public health problem, defined as fewer than 4 incident cases per 100,000 women annually, with targets for vaccination, screening, and treatment coverage. Although the United States has the tools to approach near-elimination, disparities in healthcare access and screening persist, particularly among women with HIV.",[66,28,67,68],"Human Immunodeficiency Virus (HIV)","Cervical Cancer","Cervical Precancer",[70],"screening","2026-06-04",{"date":73,"type":42},"2026-06-05",{"date":75,"type":21},"2026-06",{"date":77,"type":21},"2027-05",{"name":79,"class":80},"UNC Lineberger Comprehensive Cancer Center","OTHER",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":89,"minAge":59,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":50},"100638783","testing-the-feasibility-of-different-hpv-screening-and-care-strategies-for-women-living-with-hiv-100638783","NCT07576842","Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV","CASCADE: A Feasibility Study of HPV Screening and Management Strategies Utilizing Extended Molecular HPV DNA Genotyping and HPV Viral Load in Women Living With HIV","Inclusion Criteria:\n\n* HIV-1 infection, as documented by:\n\n  1. any FDA-approved, licensed HIV rapid test performed in conjunction with screening (oral immunoblot, ELISA test kit, and confirmed by Western blot or other approved test), OR\n  2. a physician's written record that documents HIV infection with supporting information on the participant's relevant medical history and\u002For current management of HIV infection, OR\n  3. documentation of a prescription of an approved antiretroviral regimen by either possession of pill bottles or packages with prescriber's name or ARVs dispensed from an HIV clinical treatment program with participant identifiers affixed to the bottles or packages.\n* Aged 25 or older.\n* Ability to understand and the willingness to sign a written informed consent document by the participant or by the legal representative(s) of the participant.\n* Have an intact cervix.\n\nExclusion Criteria:\n\n* Current symptoms or concern for cervical cancer.\n* History of cervical, vulvar, vaginal, perianal, anal cancer or oral cancer or current symptoms of cervical, vulvar, vaginal, perianal, anal cancer or oral cancer.\n* Have undergone cervical hHSIL treatment in the past year.\n* Have a history of hysterectomy with removal of the cervix.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including opportunistic infections of AIDS and\u002For genitourinary infections), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Any other medical condition or social situation that would put the participant, the study staff, or the study outcomes at risk, as determined by the site investigators.","FEMALE",{"count":91,"type":21},750,[93],"NA","The overall goal of this study is to inform the design and establish feasibility for a future clinical trial to determine the optimal management of women living with HIV (WLWH) with high-risk human papillomavirus (hrHPV) detected on HPV-based cervical cancer screening. WLWH have a higher diversity of anogenital HPV types causing cervical high-grade squamous intraepithelial lesions (hHSIL) and invasive cancer compared to women without HIV. While there is consensus that women testing positive for HPV 16 and\u002For 18 should be immediately managed and treated, optimal management strategies for women with other hrHPV types (non-16\u002F18) are not well defined.\n\nThis prospective cohort study will enroll WLWH undergoing cervical cancer screening using primary HPV testing. Women will self-collect vaginal specimens for hrHPV testing using the Abbott Alinity m HPV assay, which provides extended HPV genotyping and a proxy for HPV viral load based on cycle threshold (CT) values. Women with hrHPV detected will return for further evaluation and treatment as indicated. A subset of women will return at Month 6 for repeat evaluation.\n\nThe study will evaluate feasibility for a future trial by examining recruitment, retention, return for evaluation, and completion of treatment. It will also explore management strategies for women with non-16\u002F18 hrHPV based on extended genotyping and HPV viral load compared to standard of care approaches using visual inspection with acetic acid (VIA).",[28,96,67,66,97],"HPV Associated Cancers","Cervical Intraepithelial Neoplasia (CIN)","2026-05-04",{"date":100,"type":42},"2026-05-08",{"date":102,"type":21},"2026-06-01",{"date":104,"type":21},"2027-06-01",{"name":106,"class":80},"University of California, San Diego",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":58,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":81},"100612078","the-effect-of-a-transtheoretical-model-based-educational-intervention-on-first-year-nursing-students-hpv-knowledge-health-beliefs-and-vaccination-behavior-intentions-100612078","NCT07248904","The Effect of a Transtheoretical Model-Based Educational Intervention on First-Year Nursing Students' HPV Knowledge, Health Beliefs, and Vaccination Behavior Intentions","Inclusion Criteria:\n\n* First-year students enrolled in the Nursing Department of the Faculty of Health Sciences\n* Provide written informed consent to participate\n* Agree to attend all educational sessions and data collection appointments during the study period\n* Have sufficient Turkish literacy to read and understand study materials\n* Have not previously received any comprehensive education about HPV infection or HPV vaccination\n\nExclusion Criteria:\n\n* Students who do not agree to participate in the study\n* Students who do not provide written informed consent",{"count":114,"type":21},88,[93],"The purpose of this study is to examine the impact of a structured educational program based on the Transtheoretical Model (TTM) on HPV knowledge, health beliefs, and vaccination behavioral intentions among first-year nursing students. The study will also evaluate how the intervention affects students' HPV vaccine readiness compared to the TTM.\n\nThe primary questions addressed by the study are:\n\n* Does the TTM-based educational intervention increase students' knowledge about HPV and the HPV vaccine?\n* Does the program change students' health beliefs regarding susceptibility, severity, benefits, and barriers to HPV and the HPV vaccine?\n* Does the program improve students' intentions and readiness to receive the HPV vaccine?\n* Do students move to a higher behavioral readiness stage (from Precontemplation to Contemplation, Preparation, Action, or Maintenance) after the intervention?\n\nThe researcher will compare the TTM-based educational intervention with a control group that did not receive structured education to determine whether a personalized, stage-based approach is more effective in improving HPV-related outcomes among nursing students.\n\nParticipants will:\n\n* Complete baseline questionnaires measuring HPV knowledge, health beliefs, and vaccination intention.\n* The experimental group (intervention group) will receive personalized TTM-based education, face-to-face instruction in modules aligned with the five TTM phases (Precontemplation, Contemplation, Preparation, Action, and Maintenance).\n* The experimental group will participate in educational sessions designed to raise awareness, correct misinformation, support decision-making, and encourage protective behaviors.\n* The control group will not receive any educational program.\n* All participants in the experimental and control groups will complete the same questionnaires again to assess changes after the intervention.\n\nThe TTM-based educational intervention provides:\n\n* Staged counseling\n* Information about HPV and the HPV vaccine\n* Activities to raise awareness, strengthen motivation, and support vaccination adoption\n* Personalized feedback based on student readiness\n* Structured modules focusing on knowledge, belief, and behavior change strategies\n\nThe study population included first-year nursing students enrolled in the Faculty of Health Sciences. A total of 88 participants will be recruited and randomly assigned to either the intervention (n=44) or control (n=44) groups through simple randomization.\n\nThe results of this study are expected to contribute to the development of evidence-based education strategies in nursing, support of behavioral change models in health education, and strengthen the role of future nurses in HPV prevention, vaccine advocacy, and public health practice.",[28,118,119,120,121],"Papillomavirus Vaccines","Health Knowledge, Attitudes, Practice","Students, Nursing","Health Behavior","RECRUITING","2026-03-26",{"date":125,"type":42},"2026-03-27",{"date":127,"type":42},"2026-01-16",{"date":129,"type":21},"2026-04-30",{"name":131,"class":80},"Cukurova University",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100480719","the-role-of-circulating-tumour-dna-in-head-and-neck-cancer-100480719","NCT05539638","The Role of Circulating Tumour DNA in Head and Neck Cancer","Inclusion Criteria:\n\n* Patients with oropharyngeal squamous cell carcinoma\n* Both HPV positive and negative disease\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Those who lack capacity to consent\n* Patients with non-squamous cell carcinoma\n* Patients with squamous cell carcinoma out with the oropharynx",{"count":139,"type":21},250,"Cancers of the throat, oropharyngeal squamous cell carcinoma (OPSCC), are highly prevalent across Scotland. Over the past 10 years, both global and Scottish cases of OPSCC have increased, particularly those associated with human papillomavirus (HPV). However there has been little change in techniques for diagnosis and monitoring. Although imaging technologies are improving, results of imaging are often indeterminate and clinicians require additional tools to make informed decisions. With this in mind our research team have established a range of blood- based tests which detect and monitor cancer DNA fragments shed by tumours into the blood stream in OPSCC patients. Our initial studies have shown that such tests, which are minimally invasive compared to surgical biopsy, hold the potential to provide an accurate, \"real-time\" method to monitor patient response to treatment, identify early relapse and assist in clinical decision making. The investigators aim to expand these results to assist clinical decisions for both virally associated and non-viral associated OPSCC. Following this, the investigators will focus on the poorest prognosis OPSCC group (non-HPV tumours) by applying state-of-the-art DNA detection and sequencing technologies to analyse tumour- derived DNA fragments in the bloodstream, to follow treatment response and to develop new methods for detecting relapse and resistance to treatment in OPSCC. Ultimately, the investigators envisage that the implementation of such genetic assays of tumours and the fragments that they release into the bloodstream will provide a transformative shift in the clinical assessment and quality of life of OPSCC patients in Scotland.",[142,28],"Oropharyngeal Squamous Cell Carcinoma","2026-03-13",{"date":145,"type":42},"2026-03-17",{"date":147,"type":42},"2022-08-14",{"date":149,"type":21},"2027-08-31",{"name":151,"class":80},"University of Edinburgh",5,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":58,"sex":89,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":171,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":50},"100578795","validation-of-a-lab-free-low-cost-screening-test-for-prevention-of-cervical-cancer-100578795","NCT06815939","Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer","Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer: Automated Visual Evaluation","OPTICS","Inclusion Criteria:\n\n* Women between 30 and 59 years of age\n\nExclusion Criteria:\n\n* Pregnancy at the time of colposcopy\u002Fbiopsy\n* Hysterectomy with surgically absent cervix\n* HPV test in the last 5 years independently of negative or positive result\n* Previous cervical cancer diagnosis or treatment in the last 5 years\n* Lack of willingness or capacity to provide informed consent","30 Years","59 Years",{"count":164,"type":21},10000,[93],"The purpose of this study is to validate Automated Visual Evaluation (AVE), specifically the CINFinder version developed by DL Analytics, a point-of-care screening and triage diagnostic tool for cervical cancer based on the assessment of digital images through artificial intelligence. Several teams around the world have developed versions of AVE as a triage technology but none as a screening tool.",[28,168,169,170],"Cervical Intraepithelial Neoplasia","Uterine Cervical Neoplasms","Cervical Cancers",[172,67,173,174,175,176,177,178,179,180,181,182,183,184,185,186,169],"Human Papillomavirus","Screening","Neoplasms","Precancerous Conditions","Uterine Diseases","Uterine Cervical Diseases","Genital Diseases, Female","Female Urogenital Diseases and Pregnancy Complications","Urogenital Diseases","Genital Diseases","Uterine Neoplasms","Genital Neoplasms, Female","Urogenital Neoplasms","Neoplasms by Site","Uterine Cervical Dysplasia","2026-01-27",{"date":189,"type":42},"2026-01-29",{"date":191,"type":42},"2025-02-12",{"date":193,"type":21},"2026-12-31",{"name":195,"class":196},"DL Analytics","INDUSTRY"]